Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
59 results about "Symptom Cluster" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The typical symptoms of cluster headache include grouped occurrence and recurrence (cluster) of headache attack, severe unilateral orbital, supraorbital and/or temporal pain.
Electrical and magnetic stimulators used to treat migraine/sinus headache and comorbid disorders
Non-invasive electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including sinus symptoms that resemble an immune-mediated response (“sinus” headaches), irrespective of whether those symptoms arise from an allergy that is co-morbid with the headache. The disclosed methods may also be used to treat other disorders that may be co-morbid with migraine headaches, such as anxiety disorders. In preferred embodiments of the disclosed methods, one or both of the patient's vagus nerves are stimulated non-invasively. In other embodiments, parts of the sympathetic nervous system and / or the adrenal glands are stimulated.
Owner:ELECTROCORE
Methods and Compositions for Treating Migraine Pain
InactiveUS20100029665A1Benefit maximizationEliminate side effectsBiocideNervous disorderHeadache severeVascular headache
Owner:MEYERSON LAURENCE R +3
Methods and compositions for treating migraine pain
InactiveUS20060240043A1Low variabilityMaximizes therapeutic benefitBiocideBacterial antigen ingredientsHeadache severeHeadaches
The present invention provides novel methods and compositions for the treatment and prevention of headaches, vascular headaches, migraine headaches, cluster headaches, and migraine. One of the headaches, vascular headaches, migraine headaches, cluster headaches, and migraine treated by the methods and compositions of the invention is migraine.
Owner:NEUROMOLECULAR INC +1
Use of Anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
ActiveUS20120294802A1Reduce vasodilationInhibit and prevent photophobiaSenses disorderNervous disorderDiseaseAntibody fragments
The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like.
Owner:UNIV OF IOWA RES FOUND +1
Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
InactiveUS20070065463A1Improve efficiencyGood patient acceptanceBiocideBacterial antigen ingredientsMuscular spasticityTopical treatment
The invention is directed to topical formulations and methods of treating a migraines and / or cluster headaches, muscle sprains, muscle spasms, spasticity, tension headaches, tension related migraines and related conditions associated with muscle tension and pain with a therapeutically effective amount of an ergot alkaloid, skeletal muscle relaxant, serotonin agonist, combinations thereof, pharmaceutically acceptable salt thereof, prodrugs thereof or derivative thereof.
Owner:AFGIN PHARMA
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ActiveUS20090220489A1Reduce developmentDelay progressOrganic active ingredientsNervous disorderVasomotor symptomCluster headache
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Owner:TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Benzamide derivative or salt thereof
InactiveUS20070167444A1Strong inhibitory activityBiocideNervous disorderNeurogenic painOveractive bladder
There is provided a compound having a capsaicin receptor VR1 inhibitory activity and useful as a therapeutic agent for various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, bladder diseases including overactive bladder, and the like. A benzamide derivative or a salt thereof wherein a benzene ring is attached to a D ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring) through an amide bond, the benzene ring is directly bonded to an E ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring), and the benzene ring is further bonded to A (an amino moiety, a monocyclic or bicyclic heterocycle) through L (a lower alkylene).
Owner:ASTELLAS PHARMA INC
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ActiveUS8007794B2Reduce developmentDelay progressOrganic active ingredientsNervous disorderVasomotor symptomCalcitonin gene-related peptide
Owner:TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine
The present invention relates to a process for the treatment or prevention of indications which are selected from among the group comprising headaches, migraine and cluster headaches, this process comprising the joint administration of a therapeutically effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt thereof or a hydrate of the salt and a therapeutically effective amount of a second or third active anti-migraine medicament (B), particularly sumatriptan, zolmitriptan or dihydroergotamine or a physiologically acceptable salt thereof, and to the corresponding pharmaceutical compositions and the preparation thereof.
Owner:BOEHRINGER INGELHEIM INT GMBH
Systems and methods for electrical stimulation of sphenopalatine ganglion and other branches of cranial nerves
ActiveUS20140214120A1Convenient and rapid transnasal placementAvoiding any potential damageHead electrodesExternal electrodesCranial nervesElectrical impulse
Devices, systems and methods are disclosed for modulating cranial nerves, such as the sphenopalatine ganglion, to treat a medical condition of a patient, such as cluster headache. A stimulation device is advanced transnasally to a target site at or adjacent to the nasopharyngeal mucosa posterior to the middle turbinate. Electrical impulses are applied through one or more electrodes in the stimulation device to the target nerve sufficient to modulate the nerve and treat the medical condition.
Owner:ELECTROCORE
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ActiveUS20120009192A1Reduce developmentDelay progressOrganic active ingredientsFungiVasomotor symptomCalcitonin
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Owner:TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Electrical and magnetic stimulators used to treat migraine/sinus headache and comorbid disorders
Owner:ELECTROCORE
Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine
The present invention relates to a process for the treatment or prevention of indications which are selected from among the group comprising headaches, migraine and cluster headaches, this process comprising the joint administration of a therapeutically effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt thereof or a hydrate of the salt and a therapeutically effective amount of a second or third active anti-migraine medicament (B), particularly sumatriptan, zolmitriptan or dihydroergotamine or a physiologically acceptable salt thereof, and to the corresponding pharmaceutical compositions and the preparation thereof.
Owner:RUDOLF KLAUS +8
Combination of atypical antipsychotics and 5HT-1B receptor antagonists
InactiveUS20050256112A1Reduce morbidityDifferent recognizableNervous disorderMetabolism disorderDiseaseHeadaches
The present invention relates to a pharmaceutical composition for treating, for example, a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) an atypical antipsychotic or a pharmaceutically acceptable salt thereof, (ii) a 5-HT1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT1B receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally (iii) a pharmaceutically acceptable carrier.
Owner:PFIZER INC
Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
InactiveUS20060183693A1Nervous disorderPeptide/protein ingredientsCo administrationAntimigraine drug
Owner:BOEHRINGER INGELHEIM PHARMA KG
Treatment of Post-Traumatic Stress Disorder
InactiveUS20090054403A1Increase elasticityRelieve symptomsBiocideNervous disorderCompound aAdhd symptoms
Provided are methods of treating a patient diagnosed with post-traumatic stress disorder, by administering to the patient a therapeutically effective amount of Compound A. Also provided are methods of improving resilience in a patient by administering a therapeutically effective amount of Compound A. Also provided are methods of diagnosing post-traumatic stress disorder in a patient by administering to the patient a therapeutically effective amount of Compound A and assessing at least one of sign, symptom, or symptom cluster of post-traumatic stress disorder; and diagnosing post-traumatic stress disorder in the patient if the Compound A reduces at least one of sign, symptom, and symptom cluster of post-traumatic stress disorder.
Owner:BIOTIE THERAPIES INC
Electrical and magnetic stimulators used to treat migraine/sinus headache, rhinitis, sinusitis, rhinosinusitis, and comorbid disorders
ActiveUS20160361540A9Avoid stimulationElectrotherapyMagnetotherapy using coils/electromagnetsMedical disorderDisease
Transcutaneous electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including nasal or paranasal sinus symptoms that resemble an immune-mediated response (“sinus” headaches). The devices and methods may also be used to treat rhinitis, sinusitis, or rhinosinusitis, irrespective of whether those disorders are co-morbid with a headache. They may also be used to treat other disorders that may be co-morbid with migraine or cluster headaches, such as anxiety disorders. In preferred embodiments of the disclosed methods, one or both of the patient's vagus nerves are stimulated non-invasively. In other embodiments, parts of the sympathetic nervous system and / or the adrenal glands are stimulated.
Owner:ELECTROCORE
Bicyclic CB2 cannabinoid receptor ligands
The present invention relates to non-classical cannabinoids that are ligands of the peripheral cannabinoid receptor CB2, and to pharmaceutical compositions thereof comprising as an active ingredient novel (+) alpha-pinene derivatives, which are useful for prevention and treatment of autoimmune diseases including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, diabetes mellitus type I, hepatitis, psoriasis, tissue rejection in organ transplants, malabsorption syndromes such as celiac disease, pulmonary diseases such as asthma and Sjögren's syndrome, inflammation including inflammatory bowel disease, pain including peripheral, visceral, neurophathic inflammatory and referred pain, muscle spasticity, cardiovascular disorders including arrhythmia, hypertension and myocardial ischemia, neurological disorders including stroke, migraine and cluster headaches, neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's chorea, prion-associated neurodegeneration, CNS poisoning and certain types of cancer.
Owner:PHARMOS
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ActiveUS9896502B2Reduce developmentDelay progressNervous disorderImmunoglobulins against animals/humansVasomotor symptomCluster headache
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and / or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Owner:TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Method and system to facilitate the growth of desired bacteria in a human's mouth
ActiveUS10687975B2Relieve symptomsAddressing incidenceSnoring preventionIntestinal microorganismsMicrobiome
Owner:KOVARIK JOSEPH E +1
Rufinamide for the Treatment of Post-Traumatic Stress Disorder
InactiveUS20090054414A1Reduces kindlingReduce morbidityBiocideAnimal repellantsRufinamideAdhd symptoms
Provided are methods of treating post-traumatic stress disorder with rufinamide. Also provided are methods of treating kindling and improving resilience with rufinamide. Also provided are methods of diagnosing post-traumatic stress disorder in a patient by administering to the patient a therapeutically effective amount of rufinamide and assessing at least one of sign, symptom, or symptom cluster of post-traumatic stress disorder; and diagnosing post-traumatic stress disorder in the patient if the rufinamide reduces at least one of sign, symptom, and symptom cluster of post-traumatic stress disorder.
Owner:SYNOSIA THERAPEUTICS
Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
The invention relates to inhalable powders in the form of stable, spray-dried microparticles (embedding particles) for pulmonary or nasal inhalation, containing the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) or a physiologically acceptable salt thereof and one or more excipients, processes for preparing such microparticles and the use thereof for preparing a powder inhalant for the treatment of headaches, migraine and cluster headache.
![Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder](https://images-eureka.patsnap.com/patent_img/40c0f1df-a924-45b9-ac7b-8de44dfff593/US20050042178A1-20050224-C00001.png "Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder")
![Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder](https://images-eureka.patsnap.com/patent_img/40c0f1df-a924-45b9-ac7b-8de44dfff593/US20050042178A1-20050224-C00002.png "Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder")
![Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder](https://images-eureka.patsnap.com/patent_img/40c0f1df-a924-45b9-ac7b-8de44dfff593/US20050042178A1-20050224-C00003.png "Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder")
Owner:BOEHRINGER INGELHEIM INT GMBH
PACAP antibodies and uses thereof
ActiveUS10822408B2Nervous disorderPharmaceutical delivery mechanismAntiendomysial antibodiesAdenylyl Cyclases
Owner:AMGEN INC
1-substituted tetrahydroisoquinoline compound
Provided is a compound useful as an N-type Ca2+ channel blocker. As a result of intensive studies of compounds having an action of blocking N-type Ca2+ channels, the present inventors found that a tetrahydroisoquinoline compound of the present invention having a substituent at the 1-position has an action of blocking the N-type Ca2+ channels, an antinociceptive pain action, an antineuropathic pain action, an abdominal pain-inhibitory action and an opioid-induced constipation-improving action, and the present invention has been completed based on these findings. The compound of the present invention can be used as a pharmaceutical composition for preventing and / or treating various pains such as neuropathic pain and nociceptive pain, headaches such as migraine and cluster headache, central nervous system diseases such as anxiety, depression, epilepsy, cerebral stroke and restless legs syndrome, abdominal symptoms such as abdominal pain and abdominal distension, stool abnormalities such as diarrhea and constipation, digestive system diseases such as irritable bowel syndrome, urinary system diseases such as overactive bladder and interstitial cystitis, etc.
Owner:ASTELLAS PHARMA INC
Psychedelic treatment for headache disorders
PendingUS20210236523A1Reduce the burden onNervous disorderAntipyreticHeadache severeHeadache Disorders
A method of treating headache disorders, by administering an effective amount of a composition of a psychedelic to the individual and treating the headache disorder. A method of treating migraine headache in an individual, by administering an effective amount of a psychedelic to the individual and reducing migraine headache burden. A method of treating cluster headache in an individual, by administering an effective amount of a psychedelic to the individual and reducing cluster headache burden. A method of treating headache disorders, by administering a single treatment of a psychedelic to an individual and providing a long term effect in preventing headaches.
Owner:YALE UNIV +1
Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
ActiveUS20120114741A1Quick treatmentEliminate side effectsBiocideNervous disorderTopical treatmentSerotonin Agonist
Owner:DEF LLC
Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
This invention relates to the administration of novel substituted tryptamines and related derivatives for the treatment of several types of medical conditions, such as prostate conditions, impotence, cardiovascula disorders, central nervous system and psychiatric disorders (such as sleep disorders, epilepsy and other convulsive disorders, anxiety, neurodegenerative diseases), chronobiological-based disorders (such as jet lag, delayed sleep syndrome, shift-work-associated sleep disorder or seasonal affective disorder), endocrine indications, neoplastic conditions, conditions associated with senescence, ophthalmological diseases, cluster headaches and migraines, and weight gain disorders.
Owner:NEURIM PHARMA
Migraine, headache, chronic pain treatment, and prophylaxis options
InactiveUS20190135927A1Improve qualificationRelieve painNervous disorderAntipyreticChronic painMonoclonal antibody
Disclosed is method comprising administering anti-CGRP medications or monoclonal antibodies to CGRP and / or its receptors with neuroaugmentation to decrease pain associated with headache or chronic pain, for example migraine or cluster headache, or facial pain such as peripheral neuropathy.
Owner:BHL PATENT HLDG
Treatment of post-traumatic stress disorder
InactiveCN101951912AReduced symptomsOrganic active ingredientsNervous disorderCompound aTraumatic Stress Disorders
Owner:生物系治疗公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com